君圣泰医药-B（02511）今日盘中大跌5.88%，引发市场关注。该公司刚刚发布了截至2024年12月31日的年度业绩报告，可能是导致股价下跌的主要原因。
根据公司公告，君圣泰医药-B 2024年度股东应占亏损为3.82亿元（人民币，下同），虽然同比收窄59.35%，但仍然处于巨额亏损状态。每股基本亏损为0.84元。值得注意的是，公司其他收入增加至6797.1万元，同比增长98.66%，主要由于政府补助增加约2850万元。
尽管公司亏损幅度有所收窄，但投资者似乎对持续亏损感到失望，导致股价大幅下跌。市场可能认为，即使有政府补助的增加，公司仍未能实现盈利，这反映了其业务模式可能存在持续性问题。此外，每股0.84元的亏损也可能引发了投资者对公司未来盈利能力的担忧，从而促使一些投资者选择抛售股票。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.